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Introduction: Shigellosis is a significant global human health problem, and Shigella is in 
charge of almost 165 million cases of this disease annually, of whom 163 million cases are in 
developing countries and 1.5 million cases are in developed countries. The main aims of the 
current survey were to identify Shigella spp. isolated from diarrheal patients by conventional 
biochemical tests, determine the antimicrobial susceptibility profiles by disk diffusion method, 
and detect the ipaH gene using the PCR assay.
Methods: The bacterial isolates were identified as Shigella spp. by microbiological tests and were 
serogrouped by the slide agglutination test. Antimicrobial susceptibility testing was performed 
using the disk diffusion method. PCR was performed to detect the ipaH gene.
Results: The Shigella strains were isolated from 522 patients with various diarrhea, includ-
ing bloody diarrhea (3%), mucoid plus bloody diarrhea (1.9%), mucoid diarrhea (3.2%), and 
watery diarrhea (3.2%). Overall, 69 (13.2%) isolates were positive for Shigella spp., of which 
34 (49.3%) serotypes were identified as Shigella flexneri, 22 (31.9%) serotypes were identified 
as Shigella sonnei, 9 (13%) serotypes were identified as Shigella boydii, and 4 (5.8%) serotypes 
were identified as Shigella dysenteriae. Antibiotic susceptibility tests revealed that the high-
est resistance percentage was related to ampicillin (82%) and trimethoprim-sulfamethoxazole 
(77%), and ciprofloxacin and ceftriaxone were the best antibiotics against Shigella isolates.
Conclusion: We concluded that Shigella spp. can be considered as an etiological agent of diar-
rhea in southwest Iran. Since the drug resistance pattern of Shigella differs geographically and 
over time within a country, continuous and regular surveillance program is necessary.
Keywords: Shigella, diarrhea, resistance, Iran
Introduction
The Shigella species are facultative intracellular gram-negative pathogens that cause 
shigellosis, which remains a significant public health concern. Shigella spp. was 
adopted as a genus of the family Enterobacteriaceae in the 1950s and serogrouped into 
the following four species: subgroup A (Shigella dysenteriae), subgroup B (Shigella 
flexneri), subgroup C (Shigella boydii), and subgroup D (Shigella sonnei).1,2
These enteric bacteria are in charge of almost 165 million cases of diarrhea annu-
ally, of whom 163 million cases are in developing countries and 1.5 million cases are 
in developed countries.3,4 The most common symptoms of shigellosis are light watery 
diarrhea, vomiting, fever, tenesmus, headache, and abdominal pain.
The illness is generally self-limiting but may become life threatening in patients 
with compromised immune systems or in the absence of adequate health care.5 Due 
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to the low infectious dose of Shigella spp. (10–100 organ-
isms) compared with other enteric pathogens, shigellosis 
is a serious public health threat.2 Lack of proper access to 
food sources and poor health care contribute to a high risk 
of morbidity and mortality in many developing countries. 
A variety of raw vegetables, salads, meat, milk, and other 
dairy products can serve as vehicles for the transmission of 
Shigella spp. Therefore, the most common causes of contami-
nation are unsanitary practices of food handlers and fecally 
contaminated water.3
All age groups are affected by Shigella, but the age group 
under 5 years is most susceptible, because of low personal 
cleanliness and partially developed immunity and absence 
of past exposures.6 The proper and effective treatment for 
the disease leads to reduce the shedding of the bacteria and 
prevent lethal outcomes.
However, because of the antibiotic resistance develop-
ment over the past half-century, the options for antimicrobial 
therapy in shigellosis are limited to a small number of drugs.7 
Over time, the antimicrobial resistance patterns of Shigella 
spp. have changed according to geographical locations and 
the treatment process became more complicated.8
The main aims of this study were to identify Shigella spp. 
isolated from diarrheal patients by conventional biochemical 
tests, determine the antimicrobial susceptibility profiles by 




This study was approved by the ethics committee of Ahvaz 
Jundishapur University of Medical Sciences, Ahvaz, Iran 
(No. IR.AJUMS.REC.1396.568). As a part of the Ahvaz 
Jundishapur University of Medical Sciences policy, written 
informed consent was obtained from all of the children’s 
parents or legal guardian of any patient under the age of 
18 years. The study was conducted in accordance with the 
Declaration of Helsinki.
study area and specimen collection
This cross-sectional study was performed in cooperation 
with Golestan teaching hospital at the Jundishapur University 
belonging to the Iranian health system in Ahvaz, Iran, during 
November 2016 to October 2017. Golestan hospital is the 
second largest university-affiliated hospital located in Ahvaz 
city (the capital of Khozestan state). Ahvaz city is located 
820 km southwest of Tehran, the capital city of Iran. Stool 
samples were obtained from 522 patients aged 2–65 years 
who were distinguished as suffering from diarrhea by the 
clinical physician.
Diarrhea means watery or loose stools, usually at least 
three times in 24 hours. Mucus or blood can appear in the 
stools with some infections. The patients undergoing anti-
biotic therapy at the time of sample collection and those 
with persistence diarrhea were not included. The specimens 
were collected in sterile plastic containers and immediately 
transported to the Department of Microbiology of the Ahvaz 
Jundishapur University of Medical Sciences for processing.
Biochemical test
The fecal specimens were cultivated on selective and dif-
ferential media, including MacConkey agar, xylose lysine 
desoxycholate (XLD) agar, and Salmonella–Shigella (SS) 
agar (EMD Millipore, Billerica, MA, USA), and then were 
incubated at 37°C for 24 hours. Identification of Shigella was 
carried out by subjecting presumptive colonies onto triple 
sugar iron (TSI) agar, methyl red (MR) broth, Voges–Pros-
kauer (VP) broth, lysine iron agar (LIA), urea broth, indole 
test, sulfide indole motility (SIM) test, and citrate utilization 
tests, and incubated for 24–48 hours at 37°C.9,10
serotyping
The bacterial isolates that were identified as Shigella by their 
morphological and biochemical features were emulsified in 
normal saline and mixed with an equal volume of specific 
Shigella antiserum (Baharafshan, Tehran, Iran). A macro-
scopic agglutination was considered as a positive reaction.11
antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed using the 
Kirby–Bauer disk diffusion method according to Clinical and 
Laboratory Standards Institute (CLSI) recommendations.12 
The susceptibilities of all isolates to different antibiotics were 
determined using ceftriaxone (CRO, 30 µg), erythromycin 
(ERY; 15 µg), ampicillin (AMP, 10 µg), chloramphenicol 
(CAM, 30 µg), nalidixic acid (NA, 30 µg), trimethoprim-
sulfamethoxazole (SXT, 25 µg), ceftazidime (CAZ, 30 µg), 
ciprofloxacin (CIP, 5 µg), cefixime (CFM, 5 µg), and gentami-
cin, (GEN, 10 µg) (Mast Diagnostics Ltd., Merseyside, UK). 
Escherichia coli ATCC 25922 was used as quality control.
Dna extraction and PcR assay
DNA was extracted from Shigella colonies grown overnight 
on nutrient agar (EMD Millipore) by the boiling method. 
Briefly, bacteria were cultured in 5 mL of trypticase soy 
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Then, 200 µL of broth culture was mixed with 800 µL of 
sterile distilled water and the suspension was heated at 95°C 
for 10 minutes.
Then, the solution was centrifuged at 12,000× g for 
5 minutes to remove any cell debris. Finally, 200 µL of the 
supernatant was stored at –20°C and used as the template for 
subsequent amplification. PCR amplification was performed 
to detect the ipaH gene in Shigella isolates.13 Amplification 
of the ipaH gene was carried out using a thermal gradient 
cycler (Eppendorf Co., Hamburg, Germany) with the fol-
lowing protocol14,15: the PCR mixture contained 2.5 mL of 
10× buffer (10 mM Tris-HCl and 50 mM KCl), 1.5 mM 
MgCl
2
, 3 µL of DNA template, 200 µM each dNTPs, 0.4 µM 
of each forward and reverse ipaH primer, 0.75 U of Taq 
polymerase, and sterilized distilled water to complete the 
reaction volume (25 µL).
The expected sizes of PCR amplicons were revealed by 
electrophoresis on 1.5% horizontal agarose gel in Tris-borate-
EDTA (TBE) buffer and stained with ethidium bromide 
(0.5 µg/mL) (SinaClon, Tehran, Iran). Primer sequences, PCR 
conditions, and the PCR product size are shown in Table 1.16
Data analysis
The data were entered and analyzed using the SPSS software, 
Version 22.0 (IBM Corporation, Armonk, NY, USA) and 
Microsoft Excel 2016 (Microsoft Corporation, Redmond, 
WA, USA) statistical software.
Results
Stool samples were obtained from 522 diarrheal patients, 
and the mean age of patients was 30±1 years, with a range 
of 2–65 years. According to stool observation and clinical 
finding, 16 (3%) patients had bloody diarrhea, 26 (4.9%) 
patients had mucoid as well as bloody diarrhea, 10 (1.9%) 
patients had mucoid diarrhea, and 17 (3.2%) patients had 
watery diarrhea. Various age groups were ≤6 years (55%), 
7–10 years (21.6%), 11–20 years (14.5%), and ≥21 years 
(8.8%). Three hundred and eighteen (60.9%) patients were 
male, and 204 (39.1%) patients were female (Table 2).
Table 1 Primers and PCR conditions for the amplification of ipaH gene
Gene Primer sequence Size of  
amplicon (bp)
PCR conditions Reference
ipaH-F 5′-gTT ccT Tga ccg ccT TTc cga Ta-3′ 500 5 minutes at 94°c; 35 cycles of 60 seconds at 
94°c, 90 seconds at 60°c, 60 seconds at 72°c, 
and 10 minutes at 72°c
16
ipaH-R 5′-gcc ggT cag cca ccc Ta-3′
Table 2 Description of groups of patients with positive result for 











≤6 years 187 (35.8) 100 (19.1) 48 (16.7)
7–10 years 60 (11.4) 53 (10.1) 13 (11.5)
11–20 years 45 (8.6) 31 (5.9) 6 (7.8)
≥21 years 26 (4.9) 20 (3.8) 2 (4.3)
Total 318 (60.9) 204 (39.1) 69 (13.2)
The patients have had various clinical symptoms, includ-
ing headache (N=322, 61.7%), vomiting (N=141, 27%), fever 
(N=384, 73.5%), and abdominal pain (N=412, 78.9%). All the 
isolates were recognized by culture and serological tests, and 
then confirmed by the PCR method. In this study, 24 people 
were excluded from the study due to the use of antibiotics 
and 13 people were diagnosed with persistent diarrhea.
Overall, 69 (13.2%) isolates were confirmed as Shigella 
spp., of which 34 (49.2%) serotypes were identified as 
S.  flexneri, 22 (31.9%) serotypes were identified as S. sonnei, 
9 (13%) serotypes were identified as S. boydii, and 4 (5.8%) 
serotypes were identified as S. dysenteriae. All 69 isolates 
produced PCR amplicons of the ipaH gene of 500 bp.
Antibiotic susceptibility tests using the Kirby–Bauer 
method revealed that the highest resistance percentage was 
related to AMP (57, 82%), and SXT, 53 (77%), followed by 
NA (48, 69%), and ERY (47, 68.1%). In addition, Shigella 
spp. were resistant to the cephalosporins, of which 38 (55%) 
isolates were resistant to CFM and 33 (48%) isolates were 
resistant to CAZ.
The results showed that CIP and CRO were the best 
antibiotics against Shigella isolates, while more than 50% of 
S. dysenteriae strains were susceptible to NA, GEN, CRO, 
and CIP. Among the S. boydii strains, 55.5% were resistant 
to AMP, CFM, CAZ, and SXT. All S. dysenteriae strains 
were resistant to AMP, erythromycin, and SXT. Antibiotic 
resistance patterns of the four Shigella stereotypes are 
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Shigellosis is a significant global human health problem, and 
a more common serious condition in developing countries.3,4 
Antibiotic therapy decreases the severity and duration of the 
infection and the fecal elimination of the organism, which in 
turn would prevent its further spread.17
The current study provides results of molecular char-
acterization and antimicrobial resistance of Shigella spp. 
isolated from diarrheal patients in Iran. In this study, shigel-
losis was seen in all age groups and patients under the age 
of 10 years were the highest, because children in this age 
are most sensitive to shigellosis primarily due to the higher 
exposure to the contaminated environment, poor sanitation, 
and personal hygiene and less effective immune responses 
to Shigella spp.18
Identification of Shigella spp. as enteric pathogens with 
a universal impact has increased during recent years. In our 
study, Shigella spp. were isolated from 13.2% of diarrheal 
patients using cultural and biochemical methods, and the 
amplification of the ipaH gene has confirmed this isolation 
rate. This rate of isolation of Shigella was similar to studies in 
Iran (14%) and Brazil (10%) and, however, was different from 
studies in India (4%) and Ethiopia (4%).19–22 Furthermore, in 
our study, male and female children were equally affected, 
which is similar to the previous studies.20,23
This investigation showed that most of the Shigella 
isolates were resistant to AMP, SXT, and NA (up to 60%). 
In addition, Shigella spp. were resistant to the CFM 
(59.5%), CAZ (55%), and CRO (43.6%). Among antibiot-
ics tested for the susceptibility of Shigella spp. isolates, CIP 
was the best with 76.6% sensitivity followed by CRO with 
44% sensitivity.
In a study performed by Jafari et al,24 more than 90% of 
Shigella isolates were susceptible to CRO, CAZ, CFM, and 
Table 3 antibiotic resistance patterns of the Shigella spp.
Antibiotics S. flexneri 
resistant, n (%)
S. sonnei  
resistant, n (%)






ampicillin 28 (82.3) 20 (90.9) 5 (55.5) 4 (100) 57 (82.6)
Trimethoprim-sulfamethoxazole 26 (76.4) 18 (81.8) 5 (55.5) 4 (100) 53 (76.8)
chloramphenicol 22 (64.7) 15 (68.1) 6 (66.6) 3 (75) 46 (66.6)
nalidixic acid 25 (73.5) 17 (77.2) 4 (44.4) 2 (50) 48 (69.5)
gentamicin 14 (41.1) 16 (72.7) 6 (66.6) 2 (50) 38 (55)
erythromycin 22 (64.7) 17 (77.2) 4 (44.4) 4 (100) 47 (68.1)
Cefixime 18 (53) 12 (54.5) 5 (55.5) 3 (75) 38 (55)
ceftazidime 15 (44.1) 10 (45.4) 5 (55.5) 3 (75) 33 (47.8)
ceftriaxone 14 (41.1) 11 (50) 3 (33.3) 2 (50) 30 (43.4)
Ciprofloxacin 5 (14.7) 7 (31.8) 2 (22.2) 1 (25) 15 (21.7)
Abbreviations: S. boydii, Shigella boydii; S. dysenteriae, Shigella dysenteriae; S. flexneri, Shigella flexneri; S. sonnei, Shigella sonnei.
CIP. In another study conducted by Mostafavi et al,25 Shigella 
serotypes have a very high level resistance to SXT and AMP 
and high level resistance to third-generation cephalosporins 
(>90% and 50% respectively).
All investigations performed in Iran during the last 
20 years revealed a high level of resistance to SXT and AMP. 
Less than 30% of the Shigella isolates were sensitive to either 
of these two agents in Zahedan, Mashhad, and Zanjan prov-
inces.6,25,26 The most common serotype isolated in our study 
was S. Flexneri, which was similar to Jomezadeh et al’s report 
in Iran. According to their report, S. flexneri (52.7%) was the 
most common serogroup and the most resistance was seen 
regarding the SXT (80.5%) and AMP (63.8%).8
Overall, the low resistance rate to CIP in our study showed 
that fluoroquinolones are still ideal drugs for treating the 
shigellosis in our region. Due to the limitation of fluoroqui-
nolones’ prescription in children because of their side effects, 
the third-generation cephalosporins are used as a substitute 
treatment of shigellosis.25
Conclusion
We conclude that Shigella spp. can be considered as an 
etiological agent of diarrhea with a high level of antibiotic 
resistance in Ahvaz, Iran. Also, since the drug resistance 
pattern of Shigella differs in geographical regions and over 
time within a country, continuous and regular surveillance 
programs are necessary.
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